(Q37784382)

23 August 2017

title

Hepatotoxic effects of therapies for tuberculosis (English)

1 reference

23 August 2017

0 references

1 reference

Bahaa E Senousy

1

1 reference

23 August 2017

Sanaa I Belal

series ordinal

2

1 reference

23 August 2017

Peter V Draganov

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

31 August 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

23 August 2017

published in

1 reference

23 August 2017

volume

7

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

543-556

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2010.134

23 August 2017

exact match

0 references

cites work

Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Isoniazid-associated hepatitis deaths: a review of available information

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Twenty isoniazid-associated deaths in one state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

The Neurotoxicity of Antibacterial Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Clinical efficacy and tolerability of levofloxacin in patients with liver disease: a prospective, non comparative, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Effects of four Indian medicinal herbs on Isoniazid-, Rifampicin- and Pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Early indicators of prognosis in fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

What's driving the decline in tuberculosis in Arkansas? A molecular epidemiologic analysis of tuberculosis trends in a rural, low-incidence population, 1997 2003.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of pyrazinamide: cohort and case-control analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Pyrazinamide-induced granulomatous hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Update on the treatment of tuberculosis and latent tuberculosis infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Liver injury during antituberculosis treatment: an 11-year study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Isoniazid-associated hepatitis deaths: a review of available information

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Isoniazid-induced liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

A model of isoniazid-induced hepatotoxicity in rabbits.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Spin trapping of a free radical intermediate formed during microsomal metabolism of hydrazine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Plasma hydrazine concentrations in man after isoniazid and hydralazine administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Antituberculous drugs in patients with chronic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

In vitro microsomal metabolism of hydrazine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Studies on hydrazine hepatotoxicity. 2. Biochemical findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Adverse reactions to rifampicin in antituberculosis regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Erythema multiforme-type drug eruption due to ethambutol with eosinophilia and liver dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

An official ATS statement: hepatotoxicity of antituberculosis therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of antituberculosis drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Criteria of drug-induced liver disorders. Report of an international consensus meeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatic side-effects of antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Liver Alterations in Antituberculosis Regimens Containing Pyrazinamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Effect of age and gender on the activity of human hepatic CYP3A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Zingiber officinale Roscoe prevents acetaminophen-induced acute hepatotoxicity by enhancing hepatic antioxidant status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Antituberculosis treatment-induced hepatotoxicity: role of predictive factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Influence of diet and nutritional status on drug metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Isoniazid hepatotoxicity among drug users: the role of hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Mycobacterium tuberculosisInfection in Solid‐Organ Transplant Recipients: Impact and Implications for Management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Tuberculosis in liver transplant recipients: a single Brazilian center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Overview of fluoroquinolone safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Possible gatifloxacin-induced fulminant hepatic failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Moxifloxacin-induced acute liver injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Isoniazid- and rifampicin-induced oxidative hepatic injury--protection by N-acetylcysteine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Effect of vitamin C on oxidative liver injury due to isoniazid in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Effect of chitosan supplementation on antitubercular drugs-induced hepatotoxicity in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Cimetidine inhibits the formation of the reactive, toxic metabolite of isoniazid in rats but not in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Therapeutic drug monitoring in the treatment of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Emerging drugs for active tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.134

Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis

31 March 2020

1 reference

12 December 2020

Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis

1 reference

12 December 2020

Antituberculosis drugs and hepatotoxicity

1 reference

12 December 2020

Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis

1 reference

12 December 2020

Effect of the antioxidants alpha-tocopherol acetate and sodium selenite on hepatotoxicity induced by antitubercular drugs in rats.

1 reference

12 December 2020

Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy

1 reference

12 December 2020

Acetaminophen hepatotoxicity: potentiation by isoniazid

1 reference

12 December 2020

Induction of oxidative stress in antitubercular drug-induced hepatotoxicity

1 reference

12 December 2020

Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children

1 reference

12 December 2020

Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection

1 reference

12 December 2020

Hepatoprotective effect of tocopherol against isoniazid and rifampicin induced hepatotoxicity in albino rabbits.

1 reference

12 December 2020

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis

1 reference

12 December 2020

Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats.

1 reference

12 December 2020

Isoniazid drug and food interactions

1 reference

12 December 2020

Isoniazid prophylaxis in hepatitis B carriers

1 reference

12 December 2020

Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction

1 reference

12 December 2020

Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial

1 reference

12 December 2020

Clinical use of pharmacogenomic tests in 2009

1 reference

12 December 2020

1 reference

12 December 2020

Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.

1 reference

12 December 2020

Isoniazid-rifampin-induced hepatitis in hepatitis B carriers

1 reference

12 December 2020

The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.

1 reference

12 December 2020

Isoniazid hepatitis among pregnant and postpartum Hispanic patients

1 reference

12 December 2020

Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents

1 reference

12 December 2020

[Toxicity of pyrazinamide in antituberculous treatments (author's transl)]

1 reference

12 December 2020

Acute viral hepatitis as a confounding factor in patients with antituberculosis treatment induced hepatotoxicity

1 reference

12 December 2020

Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics--part 4: aminoglycosides

1 reference

12 December 2020

Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis

1 reference

12 December 2020

Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity.

1 reference

12 December 2020

Severe hepatotoxicity due to anti-tuberculosis drugs in Spain

1 reference

12 December 2020

Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis

1 reference

12 December 2020

Use of liver function tests as predictors of rifampicin metabolism in cirrhosis

1 reference

12 December 2020

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America

1 reference

12 December 2020

Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid

1 reference

12 December 2020

What is the recommended approach to asymptomatic patients who develop a reactive PPD?

1 reference

12 December 2020

Isoniazid-associated hepatitis in 114 patients

1 reference

12 December 2020

Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo

1 reference

12 December 2020

Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.

1 reference

12 December 2020

Effect of cimetidine on hepatotoxicity induced by isoniazid-rifampicin combination in rabbits

1 reference

12 December 2020

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity

1 reference

12 December 2020

Isoniazid pharmacokinetics in kwashiorkor

1 reference

12 December 2020

Effect of Ocimum sanctum (OS) leaf extract on hepatotoxicity induced by antitubercular drugs in rats

1 reference

12 December 2020

Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis

1 reference

12 December 2020

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society

1 reference

12 December 2020

Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment

1 reference

12 December 2020

From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000

1 reference

12 December 2020

Acute liver failure caused by isoniazid in a child receiving carbamazepine

1 reference

12 December 2020

10.1038/NRGASTRO.2010.134

Identifiers

DOI

1 reference

23 August 2017

1 reference